Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 11/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244735 | 0.92 | MDM2 (0.42) | MDM2TP53GHSR | |
| SCHEMBL1319860 | 0.91 | MDM2 (0.46) | MDM2TP53GHSRKMT2AMEN1 | |
| SCHEMBL3244870 | 0.89 | MDM2 (0.52) | MDM2TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL3245804 | 0.87 | MDM2 (0.44) | MDM2TP53 | |
| SCHEMBL1319265 | 0.82 | MDM2 (0.46) | MDM2TP53GHSRKDM4EMAPT | |
| SCHEMBL1322315 | 0.81 | MDM2 (0.50) | MDM2TP53GHSRKMT2A | |
| SCHEMBL1319277 | 0.79 | MDM2 (0.56) | MDM2TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL8211051 | 0.79 | MDM2 (0.50) | MDM2TP53GHSRKMT2AMEN1 | |
| SCHEMBL1319807 | 0.78 | MDM2 (0.48) | MDM2TP53SMN1; SMN2 | |
| SCHEMBL1320616 | 0.76 | MDM2 (0.51) | MDM2TP53KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | claimed |